Search research articles
Contact Us
Filters
Showing results (131-140 of 196) with videos related to
Page
of 20
Sort By:
BJU International
|
September 11, 2024
The potential benefits of concomitant statins treatment in patients with non-muscle-invasive bladder cancer
Kang Liu, Rossella Nicoletti, Hongda Zhao, et al.
Clinical & Experimental Metastasis
|
June 8, 2024
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project
Alessandro Rizzo, Sebastiano Buti, Patrizia Giannatempo, et al.
Cancer Research Communications
|
May 12, 2025
Repurposing Amiodarone for Bladder Cancer Treatment
Francisco J Roa, Maria Roubelakis, Konstantinos Paschidis, et al.
European Urology Oncology
|
June 20, 2024
The Role of Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis
Pietro Scilipoti, Aleksander Ślusarczyk, Mario de Angelis, et al.
Cancer Immunology, Immunotherapy : CII
|
December 21, 2024
Target trial emulation to evaluate the effect of immune-related adverse events on outcomes in metastatic urothelial cancer
Renate Pichler, Josef Fritz, Sarah Maier, et al.
Clinical Genitourinary Cancer
|
June 13, 2025
Prognostic Implications of Patients With Clinically Node Positive Bladder Cancer Undergoing Radical Cystectomy
Pietro Scilipoti, Marco Moschini, Paolo Zaurito, et al.
World Journal of Urology
|
November 6, 2024
The role of re-transurethral resection of bladder tumor in patients with TaHG non muscle invasive bladder cancer
Pietro Scilipoti, Marco Moschini, Mario de Angelis, et al.
European Urology Oncology
|
April 4, 2024
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study
Francesco Massari, Veronica Mollica, Ondrej Fiala, et al.
European Urology Oncology
|
April 9, 2025
Oncological Outcomes in Bacillus Calmette-Guérin-naïve High-risk Non-muscle-invasive Bladder Cancer Patients: A Systematic Review on Current Treatment Strategies and Future Perspectives
Mattia Longoni, Pietro Scilipoti, Francesco Soria, et al.
BMC Cancer
|
May 1, 2026
Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the ARON-2<sup>EV</sup> project
Alessandro Rizzo, Francesco Ciccimarra, Stenio de Casio Zequi, et al.
Page
of 20
Search research articles
Search
Showing results (131-140 of 196) with videos related to
Sort By:
Page
of 20
BJU International
|
September 11, 2024
The potential benefits of concomitant statins treatment in patients with non-muscle-invasive bladder cancer
Kang Liu, Rossella Nicoletti, Hongda Zhao, et al.
Clinical & Experimental Metastasis
|
June 8, 2024
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project
Alessandro Rizzo, Sebastiano Buti, Patrizia Giannatempo, et al.
Cancer Research Communications
|
May 12, 2025
Repurposing Amiodarone for Bladder Cancer Treatment
Francisco J Roa, Maria Roubelakis, Konstantinos Paschidis, et al.
European Urology Oncology
|
June 20, 2024
The Role of Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis
Pietro Scilipoti, Aleksander Ślusarczyk, Mario de Angelis, et al.
Cancer Immunology, Immunotherapy : CII
|
December 21, 2024
Target trial emulation to evaluate the effect of immune-related adverse events on outcomes in metastatic urothelial cancer
Renate Pichler, Josef Fritz, Sarah Maier, et al.
Clinical Genitourinary Cancer
|
June 13, 2025
Prognostic Implications of Patients With Clinically Node Positive Bladder Cancer Undergoing Radical Cystectomy
Pietro Scilipoti, Marco Moschini, Paolo Zaurito, et al.
World Journal of Urology
|
November 6, 2024
The role of re-transurethral resection of bladder tumor in patients with TaHG non muscle invasive bladder cancer
Pietro Scilipoti, Marco Moschini, Mario de Angelis, et al.
European Urology Oncology
|
April 4, 2024
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study
Francesco Massari, Veronica Mollica, Ondrej Fiala, et al.
European Urology Oncology
|
April 9, 2025
Oncological Outcomes in Bacillus Calmette-Guérin-naïve High-risk Non-muscle-invasive Bladder Cancer Patients: A Systematic Review on Current Treatment Strategies and Future Perspectives
Mattia Longoni, Pietro Scilipoti, Francesco Soria, et al.
BMC Cancer
|
May 1, 2026
Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the ARON-2<sup>EV</sup> project
Alessandro Rizzo, Francesco Ciccimarra, Stenio de Casio Zequi, et al.
Page
of 20